Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study

Headache

Volumn 38, Issue 4, 1998, Pages 281-287

  Teall, Judith ^a   Tuchman, Michael ^b   Cutler, Neal ^c   Gross, Michael ^d   Willoughby, Ernest ^e,f   Smith, Betty ^a   Jiang, Kai ^a   Reines, Scott ^a   Block, Gilbert ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Palm Beach (Fla) Neurological Group

^c CALIFORNIA CLINICAL TRIALS   (United States)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^e Neuroservices Unit   (New Zealand)

^f Hospital

Author keywords

Headache recurrence; Migraine; Rizatriptan

Indexed keywords

RIZATRIPTAN; SEROTONIN AGONIST;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; VERTIGO;

EID: 0031899682     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3804281.x     Document Type: Article

References (18)

1. Cutler N, Mushet GR, Davis R, Clements B, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology. 1995;45(suppl 7):S5-S9.
2. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
3. Beer MS, Middlemiss DN, Stanton JA, et al. An in vitro pharmacological profile of rizatriptan. Headache. 1997;37:301. Abstract.
4. Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ. The novel anti-migraine agent rizatriptan inhibits neurogenic durai vasodilation and extravasation. Eur J Pharmacol. 1997;328:61-64.
5. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37-40.
6. Longmore J, Razzaque Z, Hargreaves R, et al. Rizatriptan selectively contracts human middle meningeal over coronary artery: comparison with sumatriptan. Cephalalgia. 1997;17:388-389. Abstract.
7. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol. 1996;53:1132-1137.
8. 1D agonist. Br J Clin Pharmacol. 1997;43:49-54.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
10. Block GA, Kramer MS, Matzura-Wolfe D, et al. Long-term exposure to rizatriptan 5-mg and 10-mg oral tablets. Headache. 1997;37:302. Abstract.
11. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol. 1991;31:295-299.
12. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia. 1997;17:647-651.
13. Gobel H, Petersen-Braun M, Heinze A. Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. Philadelphia: Lippincott-Raven. 1997;6:93-97.
14. Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol. 1996;36(suppl 2):4-7.
15. Tansey MJ, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci. 1993;114:109-116.
16. Earl NL. Clinical safety of 311C90: aggregated data from patients and volunteers to date. Eur Neurol. 1996;36 (suppl 2):8-12.
17. Earl NL. 311C90, A new acute treatment for migraine: an overview of safety. Presented at the Seventh International Headache Congress; September 1995; Toronto, Ontario.
18. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia. 1996;16:554-559.